Post-earnings recap
Reported
Tue, Nov 7, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Cytek Biosciences reported a loss per share of $0.05, significantly missing expectations. Despite this, the stock rose by 2.06%, indicating that investors may have reacted positively to other aspects of the company's performance or future potential, although specific details are not available.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.05 | N/A | -284.62% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.